Skip to main content
. 2018 Apr 10;84(6):1335–1345. doi: 10.1111/bcp.13565

Figure 3.

Figure 3

Comparison of observed and predicted plasma concentration–time profiles of BMS‐823778 following daily doses for 14 days to healthy Japanese subjects with (A) CYP2C19 extensive metabolizers (25 mg); (B) CYP2C19 intermediate metabolizers (25 mg); and (C) CYP2C19 poor metabolizers (25 mg). Observed data: open circles; mean simulated profile: black line; individual simulated profile: grey line